Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
about
Toxicity of polymyxins: a systematic review of the evidence from old and recent studiesA new strategy to fight antimicrobial resistance: the revival of old antibioticsAntibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature reviewRenal and neurological side effects of colistin in critically ill patientsThe two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria.Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort studyColistin in the 21st century.Global network analysis of drug tolerance, mode of action and virulence in methicillin-resistant S. aureus.Bloodstream infections and clinical significance of healthcare-associated bacteremia: a multicenter surveillance study in Korean hospitals.Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43.Ertapenem-induced reduction in valproate levels: case report and review of the literatureSilver enhances antibiotic activity against gram-negative bacteria.The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infectionsThe use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.Neurotoxic effects associated with antibiotic use: management considerationsComparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingHigh-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.Global challenge of multidrug-resistant Acinetobacter baumanniiPolymyxin B Nephrotoxicity: From Organ to Cell Damage.Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaTreatment options for multidrug-resistant bacteria.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patientsPolymyxin B: similarities to and differences from colistin (polymyxin E).Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium.Polymyxins revisited.Update on the treatment of Pseudomonas aeruginosa pneumonia.New information about the polymyxin/colistin class of antibiotics.Treatment of Acinetobacter infections.Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.Outcome of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa treated with aerosolized colistin in neonates: a retrospective chart review.Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update.Inhaled colistin for lower respiratory tract infections.Colistin: an update on the antibiotic of the 21st century.Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date.
P2860
Q21092897-616B242A-C233-4652-9898-0D448DF479F8Q21131083-97746F06-6312-4EF8-98AE-8A3D1A16A496Q26796605-9CC9A85C-EF0A-4262-A082-60C4BCD9D05FQ27499294-0312EFD5-8937-4A94-B14A-9FAA7FE56251Q31140261-EE32EBDB-72D0-42F4-AA1E-9DAE7F1E7B61Q33751736-746219BA-08BC-495C-AF8D-3EE617193E8BQ33847509-E78EE413-E39C-4573-BEBB-BEFBBF1C7095Q33898785-F15AF991-834E-4022-85FE-4967D1F65277Q33935403-81C924B8-9233-480B-8396-78ACACB88BA8Q34057293-DB3E540E-402B-4ABD-95F9-4F6DC12BCFF0Q34100039-71776E03-CB7C-489B-BEF8-B0E46D351BF6Q34352180-D7493F9C-5D7E-4CCD-94A2-B796427F8849Q34634695-BC716A7E-B232-42A7-947C-18350D770A08Q34652418-28726395-D302-494D-8EDE-1560874CCAE7Q34803735-DBD601AF-D951-4A8C-B80C-34447570ED2BQ34999856-475F0868-8444-44AD-9D36-B04A928935AFQ35219637-540541E8-2E58-43E5-B6FA-1F6920CB7C70Q35222421-DA7D114E-81F6-4A20-AD3B-6D2BB5FB6C09Q35541277-36401FF7-B413-4A88-9BB5-9A4DF16577B1Q35977417-8309ABA8-505B-45F8-ACE9-0556069F6627Q36095081-F0333D67-DF91-40DA-AEDF-071D947AF5BFQ36105647-A02AA062-618E-4B28-9871-4A316F5827ACQ36363261-A388CFB8-AC21-4AD3-B8B8-8A4BD642B0CEQ36607401-7089BCFF-5E60-4D4F-B84A-96A652AA107DQ36607415-85A197E8-C3DE-4910-9E32-AF16F60BDBB0Q36612595-A3C29616-1AA8-4095-A8FA-9F56A409219CQ36667079-8C455091-FAA1-4848-983A-64D672B3C052Q36960059-1D210623-62CB-4C98-92B7-BD0522A1EFA0Q37036489-C51B7CA5-859E-4CB2-AAD8-8E22242D3250Q37204246-175B6348-3CC3-4470-857C-CB3F490D6924Q37215935-394A2E9C-AD6F-4857-9DAE-EB70C4FE8FFDQ37516904-8055ACFE-7A83-4E30-B251-556BA1DBBE84Q37636150-091F686C-2295-45AE-86CA-36872407B27CQ37704397-68FE82D2-5CEB-4DDC-B354-83955C6FE351Q37869910-74A959FB-588F-405F-9089-81A9EE244EFEQ37910022-9801FE8E-49ED-43E2-89DF-BE3F59337E49Q37915360-E455D09B-EDCD-4404-A38A-B4DF7F65446AQ37983920-73286C35-4BD2-4879-B606-0EC07D966A44Q38048852-7F123F44-F1CD-448D-827D-B4878FFA4151Q38232199-45006ACC-BB4F-40A8-A313-BFD9FAE6709E
P2860
Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Combination therapy with intra ...... ients without cystic fibrosis.
@ast
Combination therapy with intra ...... ients without cystic fibrosis.
@en
type
label
Combination therapy with intra ...... ients without cystic fibrosis.
@ast
Combination therapy with intra ...... ients without cystic fibrosis.
@en
prefLabel
Combination therapy with intra ...... ients without cystic fibrosis.
@ast
Combination therapy with intra ...... ients without cystic fibrosis.
@en
P2093
P2860
P921
P1476
Combination therapy with intra ...... ients without cystic fibrosis.
@en
P2093
Argyris Michalopoulos
Elpidoforos S Soteriades
George J Sermaides
George Samonis
Sofia K Kasiakou
P2860
P304
P356
10.1128/AAC.49.8.3136-3146.2005
P407
P577
2005-08-01T00:00:00Z